CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 0.2%

CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) fell 0.2% during mid-day trading on Monday . The company traded as low as $54.37 and last traded at $54.95. 262,647 shares traded hands during trading, a decline of 86% from the average session volume of 1,824,210 shares. The stock had previously closed at $55.05.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on CRSP. Morgan Stanley raised their price target on shares of CRISPR Therapeutics from $46.00 to $48.00 and gave the company an "underweight" rating in a report on Monday, February 26th. Needham & Company LLC reaffirmed a "buy" rating and set a $90.00 price target on shares of CRISPR Therapeutics in a report on Thursday, April 11th. TheStreet upgraded shares of CRISPR Therapeutics from a "d+" rating to a "c" rating in a research report on Friday, February 23rd. Mizuho lifted their price objective on shares of CRISPR Therapeutics from $82.00 to $99.00 and gave the company a "buy" rating in a research report on Wednesday, March 6th. Finally, Wells Fargo & Company lifted their price objective on shares of CRISPR Therapeutics from $55.00 to $70.00 and gave the company an "equal weight" rating in a research report on Thursday, February 22nd. Three analysts have rated the stock with a sell rating, six have issued a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, CRISPR Therapeutics has an average rating of "Hold" and a consensus target price of $76.29.

CRISPR Therapeutics Trading Up 1.1 %

The firm has a fifty day moving average price of $72.96 and a 200 day moving average price of $63.67. The firm has a market cap of $4.72 billion, a PE ratio of -28.30 and a beta of 1.76.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its quarterly earnings data on Wednesday, February 21st. The company reported $1.10 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.15 by $0.95. The business had revenue of $201.20 million for the quarter, compared to analyst estimates of $148.72 million. The firm's revenue for the quarter was up 3253.3% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.41) earnings per share. As a group, equities analysts predict that CRISPR Therapeutics AG will post -6.24 earnings per share for the current year.

Insider Activity

In other news, CEO Samarth Kulkarni sold 20,000 shares of CRISPR Therapeutics stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $80.36, for a total value of $1,607,200.00. Following the completion of the transaction, the chief executive officer now owns 187,377 shares in the company, valued at approximately $15,057,615.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, General Counsel James R. Kasinger sold 2,801 shares of the business's stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $78.26, for a total transaction of $219,206.26. Following the completion of the sale, the general counsel now owns 60,070 shares in the company, valued at $4,701,078.20. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Samarth Kulkarni sold 20,000 shares of the business's stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $80.36, for a total value of $1,607,200.00. Following the sale, the chief executive officer now owns 187,377 shares of the company's stock, valued at approximately $15,057,615.72. The disclosure for this sale can be found here. In the last quarter, insiders sold 133,992 shares of company stock worth $9,157,835. 4.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On CRISPR Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Jump Financial LLC lifted its stake in CRISPR Therapeutics by 194.7% in the third quarter. Jump Financial LLC now owns 33,307 shares of the company's stock valued at $1,512,000 after buying an additional 22,006 shares during the last quarter. Baker Chad R acquired a new position in shares of CRISPR Therapeutics in the third quarter valued at approximately $2,365,000. Capital Advisors Inc. OK increased its holdings in shares of CRISPR Therapeutics by 7.4% in the third quarter. Capital Advisors Inc. OK now owns 231,925 shares of the company's stock valued at $10,527,000 after purchasing an additional 15,951 shares during the period. Invesco Ltd. increased its holdings in shares of CRISPR Therapeutics by 1.5% in the third quarter. Invesco Ltd. now owns 136,123 shares of the company's stock valued at $6,179,000 after purchasing an additional 2,061 shares during the period. Finally, ARK Investment Management LLC increased its holdings in shares of CRISPR Therapeutics by 19.2% in the fourth quarter. ARK Investment Management LLC now owns 8,536,104 shares of the company's stock valued at $534,360,000 after purchasing an additional 1,372,986 shares during the period. Hedge funds and other institutional investors own 69.20% of the company's stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.